An FDA compounding advisory committee backed six peptides for compounding. Frank says controlled human data is thin and reported benefits are mostly anecdotal.
Recap by typeshit. Full story at UCHealth.
A shared explainer on how eating habits and food choices matter once you begin a GLP-1 medication. General guidance, no new findings.
Williams explains how retatrutide's glucagon pathway works and cautions that knockoff Reta sold online is a real risk. FDA approval could come in late 2027 or 2028.
A brief post argues buyers need accurate information on peptides because a lot of the popular messaging is misleading.
Men's Journal reports the coroner's findings on the cause of Norton's death, with the dose detail coming from the coroner rather than earlier speculation.
Dr. Jonathan Stegall shares the data: about 13 in 100 GLP-1 users with stage 1 to 3 colorectal cancer saw it spread, versus about 22 in 100 on another diabetes drug.
Reuters reported the approval as Novo shares sit down 13% this year. STEP Young data in kids aged 6 to 11 is due at ObesityWeek in November.
Loading…